Phẫu thuật ở Trung Quốc có an toàn? Giải thích có thể kiểm chứng

At a leading Chinese Grade 3A hospital, elective surgery is now comparable in safety to international standards — not because of a slogan, but because accreditation, national review standards, surgical volume and quality indicators all point the same way. The honest caveat is equally important: what determines the safety of an operation is not the country label but the chain of hospital, department, operating surgeon and perioperative management. China has 38,710 hospitals and 1,876 Grade 3A hospitals; the gap between the top and the tail is far wider than the average gap between countries.

So the useful question is not "is surgery in China safe" but "what is the safety record of this hospital, this department and this surgeon, for my condition". Each section below answers that narrower question.

JCI (Joint Commission International) is the most widely recognised hospital accreditation worldwide. Its survey covers more than 1,100 measurable elements: patient safety and rights, clinical care standards, infection prevention, medication management, staff credentials and training, facility safety, quality improvement and international patient services. The number of mainland Chinese hospitals holding a valid JCI certificate varies widely by source (from a few dozen to just over a hundred), because accreditation runs for three years and the directory changes every year — roughly 0.2–0.3% of all hospitals.

Two scopes must never be confused. Whole-hospital accreditation means every ward meets JCI standards. International-department-only accreditation means only the VIP or international unit is surveyed — ordinary wards are not. Many well-known public hospitals fall into the second category, so if you are admitted to a regular ward you are not receiving JCI-standard processes. Ask directly which scope applies and when the last re-survey took place, then check the hospital's English name in the JCI directory yourself. A logo on a website proves nothing.

Other credentials worth checking: ISO 15189 for medical laboratories and CAP for pathology (these determine how reliable your test and biopsy reports are), AAHRPP where clinical trials are involved, and the regulatory layer — China's NMPA joined the ICH in 2017, aligning drug review with international standards, and China now registers the second-largest number of clinical trials worldwide, with many global multi-centre trials running locally. The Boao Lecheng pilot zone in Hainan additionally allows compassionate use of drugs and devices not yet approved on the mainland.

Know the limits too: accreditation proves the hospital has systems to detect and correct problems. It does not prove the hospital is the best place for your particular disease. Accreditation answers process safety; specialty strength needs a different set of indicators.

Chinese hospitals are graded by scale, technology, equipment and academic capacity into Grade 1, 2 and 3, each subdivided into A, B and C. Grade 3 hospitals are the highest tier and carry responsibility for complex regional care, teaching and research; Grade 3A is the top band within that tier. According to the National Health Commission's 2024 Statistical Bulletin, China had 38,710 hospitals at the end of 2024, of which 4,111 were Grade 3 and 1,876 were Grade 3A — under 5% of all hospitals, handling most complex cases.

The baseline requirements for Grade 3 include: bed capacity (typically 500 or more), a full set of clinical and technical departments, mandated staffing and nurse-to-bed ratios, major equipment, teaching and research capacity, and the ability to receive referrals and run consultations across a region.

Assessment follows the 2020 Grade 3 Hospital Review Standard. It has three parts: prerequisite requirements (licensing, public-interest obligations, adverse-event management — any failure is disqualifying); monitored quality and safety data (DRG/DIP capability, case-mix index, low-risk group mortality, surgical complication rates, antimicrobial use intensity); and an on-site survey that traces a real patient's pathway to check whether written policy is actually practised.

The most common marketing trap: Grade 3A is a hospital-level grade, not a department-level one. The same hospital can rank top ten nationally in cardiac surgery and be unremarkable in another specialty. For a specific procedure, check four things: position on the Fudan specialty reputation list, national key specialty status, the surgeon's annual case volume, and the complication and re-operation rates for that procedure.

Grade 3A and JCI are often misunderstood as rivals. Grade 3A is a mandatory government review covering every Grade 3 hospital; JCI is voluntary, paid and re-surveyed every three years. The first guarantees a floor and scale, the second verifies execution against international standards. They are complementary.

Chinese physicians hold one of four ranks: resident, attending, associate chief physician and chief physician, each with minimum years, clinical requirements and formal review. In parallel, surgery is classified into four levels by risk and complexity; Level 4 procedures (high risk, high difficulty, major organs) must be led or supervised on site by an associate chief physician or above with the matching credentials. This is written into the national core quality and safety rules.

Seniority signals are worth checking: membership of the Chinese Academy of Sciences or Chinese Academy of Engineering, National Science Fund for Distinguished Young Scholars, Changjiang Scholars, leadership of a national key specialty, and doctoral supervision. Department heads at top hospitals often serve as president or vice-president of national specialty societies and help write national guidelines.

Training is now standardised: a three-year national residency programme plus specialty training, so young surgeons complete a large volume of first-assistant work before independent operating. Many mid-career surgeons at leading hospitals have trained abroad.

For international patients the practical rule is to ask three questions before surgery: who is the operating surgeon, how many of exactly this procedure does he or she perform each year, and why this approach rather than another. A reputable hospital answers in writing and provides an English CV. Vague answers about an "expert team" with no name are a warning sign.

In 2024 China recorded 10.15 billion outpatient visits and 312 million inpatient admissions — the largest surgical system in the world. Leading general hospitals perform roughly 80,000–200,000 operations a year, and specialist centres concentrate further: the National Centre for Cardiovascular Diseases (Fuwai Hospital) performs over 15,000 cardiac operations annually, and the Zhongshan Ophthalmic Center runs cataract volumes in the tens of thousands.

The volume–outcome relationship is one of the most replicated findings in surgery: centres with higher annual case numbers for a given procedure tend to have shorter operating times, fewer complications, shorter stays and lower mortality, because teamwork, anaesthesia, ICU support and complication management have become routine. This is precisely why, for cross-border care, you choose a specialist centre rather than simply the biggest hospital in the biggest city.

Technology is deployed at scale: several hundred robotic systems are installed, with mature programmes in radical prostatectomy, joint replacement, lobectomy and hepatobiliary-pancreatic surgery; domestic laparoscopic and orthopaedic navigation robots are spreading quickly. Proton and heavy-ion therapy is commercially operating in Shanghai, Shandong and Hebei.

One caution: look at the volume for your procedure, not the hospital's total. A hospital doing 150,000 operations a year may do a few dozen of a rare procedure; conversely a specialty hospital with modest totals may have extremely high concentration in one operation.

The most quoted comparison is overall five-year cancer survival: about 43% in China (National Cancer Center) versus about 68% in the United States (SEER). The gap is real, but it does not mean a 25-point technical deficit. Three factors drive it: case mix (lung, oesophageal, gastric and liver cancers — all with poorer prognosis — are more common in China); stage distribution (later diagnosis, and survival is highly stage-sensitive); and screening intensity (earlier detection of prostate and breast cancer in the US lifts the overall figure).

Far more meaningful is single-disease, same-stage comparison. Nasopharyngeal carcinoma (Sun Yat-sen University Cancer Center is the global benchmark), oesophageal, gastric and liver cancer surgery in major Chinese centres are internationally leading; in-hospital mortality for elective coronary bypass at leading centres is below 1%; one-year survival after living-donor liver transplantation exceeds 90%; and CAR-T therapy for relapsed or refractory lymphoma achieves complete response rates of 50–80% at roughly one tenth of US pricing.

Whenever you see an outcome figure, ask four questions: which year, how many cases, which stage, single- or multi-centre. A percentage with no denominator and no date is marketing, not evidence.

Chinese quality management rests on 18 core patient-safety rules. Those directly relevant to surgery include: first-contact responsibility, three-tier ward rounds, pre-operative discussion, surgical safety checklist, surgical grading and privileges, difficult-case discussion, mortality review, critical-value reporting, graded antimicrobial prescribing and blood transfusion review.

The WHO surgical safety checklist is standard practice in Grade 3A hospitals, at three points — before anaesthesia induction, before incision, and before the patient leaves the theatre — with surgeon, anaesthetist and theatre nurse confirming identity, site and procedure, implants and instruments, expected blood loss and allergies together. This is not ceremony; it is an intervention shown to reduce surgical error and mortality.

External pressure reinforces it: single-disease quality control and clinical pathways standardise common operations; DRG/DIP payment reform turns low-risk group mortality, time-consumption and cost-consumption indices into hospital performance metrics; and infection control is monitored through surgical site infection rates, resistant-organism surveillance and hand-hygiene compliance, with an infection management department in every Grade 3 hospital.

If something does go wrong, the route is defined: the 2018 Regulation on the Prevention and Handling of Medical Disputes provides four channels — negotiation, people's mediation, administrative mediation and litigation — with medical dispute mediation committees in every province and liability insurance common at Grade 3A hospitals. International patients should keep complete records of every conversation; in any dispute that is the core evidence.

Language and consent. Insist on a consent form you can read, and confirm the key risks face to face — bleeding, infection, nerve injury, re-operation, extended ICU stay — with a written record. Relying on verbal relay through an interpreter is the single most common cross-border hazard.

Records and imaging. Arriving with reports but no source data is a leading cause of misjudgement. Bring original DICOM imaging (disc or secure cloud link), pathology slides and blocks, previous operative notes and a medication list; have translation done by the hospital's international department or a professional medical translator.

After discharge, confirm three things before you leave: a named contact for complications with hours of availability, a follow-up schedule, and a written 30-day medication plan. Long-haul flights carry venous thromboembolism risk — most procedures advise against flights longer than four hours for about four weeks; follow your surgeon's specific instruction.

Cost and insurance. Most international policies exclude planned treatment abroad; establish in advance whether direct billing is available or you will be reimbursed, and obtain the claim document list. Ask for a written cost estimate that states how an extended stay for complications is charged.

Medication compliance. Anaesthetics and opioid analgesics are strictly controlled across borders — do not carry them home. For long-term medication, request an English prescription and package insert.

Everything above compresses into a checklist. Any provider that cannot answer these within two hours is not the right place for your operation.

• ① Is it Grade 3A, and is your specialty a national key specialty — the floor and the national credential.
• ② Does it appear near the top of the Fudan specialty reputation list — peer assessment of complex cases.
• ③ Is the international department JCI-accredited, at whole-hospital or department scope, and when was the last survey?
• ④ What is the surgeon's annual volume for your exact procedure and his or her sub-specialty focus?
• ⑤ Can it provide English records, a written cost estimate, a complication protocol and a follow-up plan?

Sources: National Health Commission, Statistical Bulletin on China's Health Development 2024 (hospital and Grade 3A counts, admissions, physician numbers, average costs); Fudan University Hospital Management Institute, 2022 China Hospital Specialty Reputation Ranking; National Cancer Center survival reports; US SEER database for comparison; JCI official accredited-organisation directory for accreditation status.

Statistical definitions and publication dates differ, so figures are not perfectly comparable, and rankings, accreditation status and appointments change continuously. This page explains the system and helps you shortlist hospitals; it is not medical advice and cannot replace a licensed physician's assessment of your own case. Treatment decisions must follow the written opinion of the treating hospital and surgeon.